Cannabinoid Desensitization Occurred Without Gross Cell Damage in a Neuroblastoma Experiment

A 1988 cell study found reduced cannabinoid responsiveness on a cyclic-AMP endpoint without corresponding gross morphological changes under the assessed conditions. Functional desensitization and observable cell injury were different questions.

The system was a defined cell line

Investigators studied N18TG2 neuroblastoma cells exposed to THC or an experimental cannabinoid-related compound. They measured cellular growth, protein content, morphology and signaling. These are in-vitro observations, not direct assessments of human brain health.

Several injury-related comparisons were negative

Selected exposures did not significantly change growth or protein content, and cellular structures appeared intact on the reported microscopy assessments. These negatives are bounded by concentration, duration and method. They do not establish that every possible cellular effect was absent.

The signaling response still changed

After prolonged exposure, cannabinoid inhibition of cyclic-AMP accumulation became weaker. The authors described homologous desensitization across the two compounds. This illustrates that an altered response can occur without a detectable gross structural change, while leaving other biological questions unresolved.

Interpreting the evidence

The study supports separating functional adaptation from the particular injury measures assessed. It does not prove general cannabinoid safety or equate a cultured cell's response with tolerance, dependence or impairment in a person. The supplied abstract is truncated, so additional results are not assumed.

Related reading: interpreting cannabis tolerance claims.

Research reference

Dill JA; Howlett AC (1988). Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us